| 0 (0%) | 09-27 09:27 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.85 | 1-year : | 8.98 |
| Resists | First : | 7.57 | Second : | 7.69 |
| Pivot price | 7.56 |
|||
| Supports | First : | 7.4 | Second : | 6.15 |
| MAs | MA(5) : | 7.55 |
MA(20) : | 7.54 |
| MA(100) : | 7.59 |
MA(250) : | 7.72 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 28.2 |
D(3) : | 41.4 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 8.31 | Low : | 6.9 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MSD ] has closed above bottom band by 20.1%. Bollinger Bands are 20.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.59 - 7.63 | 7.63 - 7.66 |
| Low: | 7.38 - 7.43 | 7.43 - 7.47 |
| Close: | 7.44 - 7.52 | 7.52 - 7.58 |
Thu, 25 Sep 2025
Evaxion Out-Licenses Vaccine Candidate EVX-B3 to MSD - TipRanks
Thu, 25 Sep 2025
MSD partners with Leadership Duncan 30 to restore Christmas parade route - Duncan Banner
Thu, 25 Sep 2025
MSD pays up to nearly $600m for Evaxion’s mystery vaccine candidate - Pharmaceutical Technology
Thu, 25 Sep 2025
Evaxion out-licenses vaccine candidate EVX-B3 to MSD - The Pharma Letter
Thu, 25 Sep 2025
Evaxion vaccine sold to MSD: "A historic moment for us" - medwatch.com
Thu, 25 Sep 2025
Evaxion Biotech stock soars after MSD licenses its vaccine candidate - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 20 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 43.2 (%) |
| Shares Short | 22 (K) |
| Shares Short P.Month | 42 (K) |
| EPS | 0.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.5 |
| Profit Margin | 84.4 % |
| Operating Margin | 87 % |
| Return on Assets (ttm) | 6.6 % |
| Return on Equity (ttm) | 10.6 % |
| Qtrly Rev. Growth | -20.9 % |
| Gross Profit (p.s.) | 0.95 |
| Sales Per Share | 0.95 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 9.38 |
| PEG Ratio | 0 |
| Price to Book value | 1 |
| Price to Sales | 7.9 |
| Price to Cash Flow | 0 |
| Dividend | 0.18 |
| Forward Dividend | 0 |
| Dividend Yield | 2.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|